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Short running head: Comparative activity of ceftaroline and ceftobiprole 
  
Background: Ceftaroline and ceftobiprole inhibit most MRSA and MDR pneumococci. Few direct 
comparisons of their activity have been published, but in several years (2008, 2013, 2017 and 2018) both were 
tested in parallel in the BSAC Resistance Surveillance Programme, giving paired results. These are reviewed. 
Methods: Isolates included were bloodstream Staphylococcus aureus [n=1884 (MRSA, n=234)], bloodstream 
CoNS, (n=813, 574 methicillin resistant) and bloodstream (n=852) and respiratory (n=670) Streptococcus 
pneumoniae. MICs were determined by BSAC agar dilution and reviewed against EUCAST breakpoints; S. 
aureus breakpoints were assumed for CoNS. 
Results: Ceftaroline MICs were mostly 2-fold lower than those of ceftobiprole, but, for all groups, MICs of 
both agents were strongly inter-related. Methicillin-susceptible staphylococci were universally susceptible to 
both agents; all MRSA were susceptible to ceftobiprole, whereas 10/234 had intermediate/high dose 
susceptibility to ceftaroline. Among methicillin-resistant CoNS, 88% were susceptible to both agents, but 
reduced ceftaroline susceptibility and ceftobiprole resistance were frequent (65%) among methicillin-resistant 
Staphylococcus haemolyticus. One S. pneumoniae was resistant to both ceftaroline (MIC 0.5 mg/L) and 
ceftobiprole (MIC 1 mg/L) and seven others were only resistant to ceftobiprole (MIC 1 mg/L); seven of these 
eight pneumococci belonged to serotype 19A or 19F. No time trend in susceptibility was seen for either 
cephalosporin. 
Conclusions: Ceftaroline and ceftobiprole have similarly good activity against staphylococci and 
pneumococci. Therapeutic choices between these agents should be predicated on other differentiating factors, 
including licensed indications, clinical experience and need for Gram-negative coverage. 
  
Introduction 
Ceftaroline fosamil (Pfizer Inc.)1 and ceftobiprole medocaril (Correvio Pharma Corp.)2 are cephalosporins 
active against most MRSA and penicillin-resistant Streptococcus pneumoniae. This reflects their ability to 
target the supplementary PBP2’ of methicillin-resistant staphylococci and the modified PBPs of penicillin-
resistant pneumococci. Licensing and post-marketing trials have demonstrated the efficacy of ceftaroline 
fosamil in skin and skin structure infection, including against MRSA, and in community-acquired pneumonia. 
Ceftobiprole medocaril has had a more chequered development pathway, with initial rejection of skin and skin 
structure infection trials by the FDA on a data quality issue,3 but the drug has since been licensed by the EMA 
for community-acquired pneumonia and hospital-acquired pneumonia, again with anti-MRSA activity 
demonstrated.4 
Although there are many publications on each of these cephalosporins individually, there are few direct 
comparisons. Both have, however, been included for several years in the BSAC Resistance Surveillance 
Programme, yielding paired results for staphylococci and pneumococci causing clinically significant 
bacteraemia and for pneumococci causing community-onset lower respiratory tract infection (LRTI). These 
data are reviewed. 
 
Materials and methods 
The BSAC Surveillance Programme has been detailed previously.5 It collects fixed quotas of isolates, by 
species, from bacteraemias and LRTIs across a panel of UK and Irish microbiology laboratories. According 
to the year, between 23 and 39 sites have participated. Collection of bacteraemia isolates runs by calendar 
year, while that of LRTI isolates runs from October in one year to September of the next year, capturing 
isolates from a ‘respiratory season’. Results were reviewed whenever ceftobiprole and ceftaroline were both 
tested in parallel during a collection year. This applied for Staphylococcus aureus, CoNS and S. pneumoniae 
bloodstream isolates in 2008, 2013, 2017 and 2018, and for respiratory S. pneumoniae isolates in 2016/17 and 
2017/18. 
Staphylococci were categorized by their coagulase reaction and, except in 2008 CoNS were identified 
to species level by MALDI-TOF MS. Methicillin resistance was defined by the presence of mecA, as 
determined by PCR.6 Pneumococci were identified by appearance and optochin susceptibility; they were 
serotyped as previously described.7 
BSAC agar dilution was used to determine MIC,5 with each isolate only tested once. Breakpoints 
followed EUCAST criteria (Version 10.0, 2020),8 with S. aureus values adopted for CoNS (ceftaroline, 
indications other than pneumonia, ≤1/>2 mg/L; ceftobiprole ≤2/>2 mg/L). 
 
Results  
Both agents were tested against a total of 4219 isolates in the four bacteraemia years and two respiratory 
seasons. MIC distributions are shown in Table 1, whilst Figure 1 cross-plots MIC data for the two 
cephalosporins. 
The staphylococci comprised: (i) 1884 S. aureus, of which 234 (12%) were MRSA; and (ii) 813 CoNS, 
of which 574 (71%) were methicillin resistant. Six hundred and thirty-three CoNS were identified to species 
level, comprising Staphylococcus epidermidis (n=424), Staphylococcus hominis (n=84), Staphylococcus 
haemolyticus (n=55), Staphylococcus capitis (n=46), Staphylococcus warneri (n=13) and others (n=11). 
Proportions of the major CoNS species did not change over the seasons studied (P=0.06). The S. pneumoniae 
panel comprised 1522 isolates, 852 from bacteraemias and 670 from LRTI. 
MICs of the two cephalosporins were inter-related across the susceptibility spectrum, with ceftaroline 
generally around 2-fold more active than ceftobiprole on a gravimetric basis (Figure 1). All the methicillin-
susceptible staphylococci were susceptible to both compounds, with MICs for methicillin-susceptible CoNS 
generally lower than those for MSSA. MICs for methicillin-resistant staphylococci were raised above those 
for their methicillin-susceptible counterparts; nonetheless, MICs for all 234 MRSA remained within the 
susceptible range for ceftobiprole (≤2 mg/L) and in the susceptible (≤1 mg/L) or, in 10/234 cases, high-dose 
susceptible/intermediate range for ceftaroline (2 mg/L) (no genotyping data for these isolates are available). 
The behaviour of methicillin-resistant CoNS was species related. Among 574 such isolates tested, 518 
were susceptible, by S. aureus breakpoints, to ceftaroline, 55 were intermediate/high-dose susceptible and 1, 
with a ceftaroline MIC of 4 mg/L, was resistant. Forty-three of the 56 isolates that were not fully susceptible 
were identified to species level [33 (77%) were S. haemolyticus, 5 were S. capitis, 3 were S. hominis and 2 
were S. epidermidis]. For ceftobiprole, 519 methicillin-resistant CoNS isolates were susceptible and 55 were 
resistant, with MICs of 4–8 mg/L (EUCAST has no intermediate category here); 41 of these 55 isolates were 
identified to species level, comprising 34 S. haemolyticus (83%), 4 S. hominis, 2 S. epidermidis and 1 S. 
capitis. There was near total overlap between the isolates with intermediate susceptibility to ceftaroline and 
those with resistance to ceftobiprole. Overall, 32/55 identified methicillin-resistant S. haemolyticus were 
resistant or intermediate to both cephalosporins compared with 1/424 methicillin-resistant S. epidermidis, 1/84 
methicillin-resistant S. hominis, 1/46 methicillin-resistant S. capitis, 0/13 methicillin-resistant S. warneri and 
0/11 among methicillin-resistant isolates of other species; the excess of resistance in S. haemolyticus was 
highly significant (P<0.001). Geometric mean MICs of ceftaroline and ceftobiprole followed a similar 
relationship to species, being highest for methicillin-resistant S. haemolyticus at 1.18 and 2.13 mg/L, 
respectively, and lowest for methicillin-resistant S. epidermidis at 0.27 and 0.89 mg/L, respectively. At the 
opposite end of the MIC spectrum, it is notable that 15/26 methicillin-susceptible CoNS isolates with 
ceftobiprole MICs ≤0.06 mg/L were identified as S. capitis; these comprised one-third of all the S. capitis 
included and 68% (15/22) of all the methicillin-susceptible S. capitis (P<0.001). 
Among the 1522 S. pneumoniae isolates, 1384 were fully susceptible to penicillin (with MICs ≤0.06 
mg/L), 135 were in the high-dose susceptible/intermediate range (with MICs between 0.12 and 2 mg/L) and 
three were resistant (with MICs >2 mg/L). The rate of full susceptibility to penicillin among bloodstream 
isolates decreased insignificantly from 97% in 2008 to 94% in 2018 (P=0.3), but was significantly lower 
among respiratory isolates (574/670, 86%) compared with bloodstream isolates (810/852, 95%) (P<0.001). 
MICs of the two cephalosporins tracked with the penicillin values; thus, the geometric mean MICs of 
ceftaroline and ceftobiprole for the penicillin-susceptible isolates were 0.007 and 0.013 mg/L, respectively, 
the geometric mean MICs of ceftaroline and ceftobiprole for the penicillin-intermediate isolates were 0.05 
and 0.12 mg/L, respectively, and the geometric mean MICs of ceftaroline and ceftobiprole for the penicillin-
resistant isolates were 0.2 and 1 mg/L, respectively. Only one S. pneumoniae isolate, from blood in 2008 and 
belonging to serotype 19F, was resistant to both ceftaroline (MIC=0.5 mg/L) and ceftobiprole (MIC=1 mg/L). 
Seven further isolates [all respiratory; 2016/17 (n=2) and 2017/18 (n=5); serotypes 19F (n=3),19A (n=3) and 
6B (n=1)] were only resistant to ceftobiprole (MIC=1 mg/L). Six isolates were MDR (resistant to at least 
penicillin, erythromycin and tetracycline). 
Mode and geometric mean MICs did not change significantly over time within the MSSA, MRSA, 
methicillin-susceptible CoNS, methicillin-resistant CoNS or pneumococci groups (Table 1), though the 
proportion of MRSA among S. aureus was higher in 2008 (25%) than in the three later years (range 12 - 6%). 
 
Discussion 
Ceftaroline and ceftobiprole had similarly good activity as each other against S. aureus, including MRSA, 
and pneumococci, with only tiny proportions of isolates showing reduced susceptibility or resistance. At this 
level, our findings corroborate those of larger surveillances for the individual compounds in the USA,9 
Canada10 and Europe.11 Resistance has been described in MRSA and is associated with PBP2’ mutations, 
but these are extremely rare in the UK, Europe or the USA, though more frequent in the Far East.12–14 In the 
case of pneumococci, as also found previously in the UK15 and Canada,16 resistance or reduced 
susceptibility was largely associated with serotypes (19F and 19A) that are covered by conjugate vaccines 
that are now widely deployed, meaning that their prevalence has diminished. 
CoNS present a more complex picture, with raised ceftaroline and ceftobiprole MICs frequent 
among methicillin-resistant S. haemolyticus, as also found previously in the UK17 and the USA.18 This 
species accounted for 65% (32/44) of CoNS isolates found resistant to ceftobiprole and resistant or (mostly) 
intermediate/high dose susceptible to ceftaroline, but for only 8.7% (55/633) of all CoNS identified to 
species level. At the other end of the MIC spectrum, extreme susceptibility to ceftobiprole (not ceftaroline) 
was a trait of methicillin-susceptible S. capitis. It should also be re-stressed here that CoNS lack formal 
breakpoints from EUCAST. We adopted S. aureus breakpoints, as have others,11 though a higher non-
species-specific pharmacokinetic/pharmacodynamic breakpoint of ≤4 mg/L has also been used9 and would 
have recategorized as susceptible all but one of the CoNS isolates categorized here as resistant to 
ceftobiprole. 
Given the similar microbiological performance of these two agents, with the lower MICs of 
ceftaroline partly offset by a higher susceptible breakpoint for ceftobiprole, we conclude that clinical choice 
of which agent to prefer in a given patient should be predicated on other factors, specifically: licensed 
indications, clinical experience and any need for concurrent Gram-negative activity. Anti-Enterobacterales 
coverage is more extensive for ceftobiprole, which has a degree of stability to AmpC enzymes,19 though not 
to ESBLs. Surveillance of Enterobacterales in Canadian hospitals found resistance to ceftaroline was more 
prevalent than to ceftobiprole, particularly in species where derepression of AmpC is frequent, 
e.g. Enterobacter cloacae.10 According to the BNF, the per vial NHS cost for each of the two agents is 
similar (£37.50 for ceftaroline and £39.60 for ceftobiprole), though total costs will depend on whether 
ceftaroline is administered as 600 mg q8h or 600 mg q12h; ceftobiprole is licensed only for a 500 mg q8h 
regimen. 
Continued collection of surveillance data is crucial for our understanding of emergence of resistance 
to or increase in MIC of newer antimicrobial agents over time, particularly for those organisms where 
limited national surveillance exists (e.g. CoNS). 
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Table 1. MIC distributions, mode MICs and geometric mean MICs of ceftaroline and ceftobiprole for staphylococci and pneumococci 
Organism (n) Agent 
MIC (mg/L) Geometric mean MIC (mg/L) 
0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 2008 2013 2017 2018 
Bacteraemia                   
   S. aureus (1884)                   
      MRSA (234) ceftaroline - - - - - - - 6 81 137 10 - - 0.54 0.35 0.48 0.48 
ceftobiprole - - - - - - - - 8 140 86 - - 1.51 0.95 1.13 1.19 
      MSSA (1650) ceftaroline - - - - - 8 140 1361 111 30 - - - 0.3 0.22 0.25 0.25 
ceftobiprole - - - - - 5 12 330 1182 113 8 - - 0.95 0.66 0.68 0.68 
   CoNS (813)                   
      methicillin-resistant CoNS (574) ceftaroline 1 - 1 - - 3 57 276 121 59 55 1 - 0.39 0.35 0.39 0.37 
ceftobiprole - - - 1 - - - 6 118 287 107 54 1 1.2 0.92 1.15 1.17 
      methicillin-susceptible CoNS (239) ceftaroline - - - 6 29 105 80 18 1 - - - - 0.09 0.08 0.07 0.07 
ceftobiprole - - - 2 5 18 45 131 33 4 1 - - 0.3 0.18 0.2 0.19 
   S. pneumoniae (852)                   
      penicillin MIC ≤0.06 mg/L (810) ceftaroline 10 236 483 51 27 3 - - - - - - - 0.01 0.01 0.01 0.01 
ceftobiprole - 12 225 509 56 7 1 - - - - - - 0.02 0.01 0.01 0.01 
      penicillin MIC 0.12–2 mg/L (41) ceftaroline - - - 9 12 12 8 - - - - - - 0.05 0.04 0.05 0.03 
ceftobiprole - - 1 5 10 4 3 9 9 - - - - 0.17 0.1 0.15 0.05 
      penicillin MIC >2 mg/L (1) ceftaroline - - - - - 1 - - - - - - - 1 - - - 
ceftobiprole - - - - - - - - - 1 - - - 0.06 - - - 
                 
2016/17 2017/18 
Respiratory                   
   S. pneumoniae (670)                   
      penicillin MIC ≤0.06 mg/L (574) ceftaroline 1 106 382 72 12 1 - - - - - - - - - 0.01 0.01 
ceftobiprole - - 117 427 22 8 - - - - - - - - - 0.01 0.01 
      penicillin MIC 0.12–2 mg/L (94) ceftaroline - - - 14 24 29 24 3 - - - - - - - 0.06 0.05 
ceftobiprole - - - 6 26 9 6 16 26 5 - - - - - 0.11 0.14 
      penicillin MIC >2 mg/L (2) ceftaroline - - - - - - - 1 1 - - - - - - 0.5 0.25 
ceftobiprole - - - - - - - - - 2 - - - - - 1 1 
EUCAST breakpoints for ceftaroline: S. aureus, ≤1/>2 mg/L; and S. pneumoniae, ≤0.25/>0.2 5 mg/L. EUCAST breakpoints for ceftobiprole: S. aureus, ≤2/>2 
mg/L; and S. pneumoniae, ≤0.5/>0.5 mg/L. S. aureus breakpoints were assumed for CoNS. 
Mode MICs are indicated in bold. 
Figure 1. MICs of ceftobiprole in relation to those of ceftaroline for S. aureus, CoNS and S. pneumoniae. 
EUCAST breakpoints for ceftaroline: S. aureus, ≤1/>2 mg/L; and S. pneumoniae, ≤0.25/>0.25 mg/L. 
EUCAST breakpoints for ceftobiprole: S. aureus, ≤2/>2mg/L; and S. pneumoniae, ≤0.5/>0.5 mg/L. S. 
aureus breakpoints were assumed for CoNS. S. aureus isolates in the high-dose susceptible/intermediate 
range for ceftaroline (MIC 2 mg/L) are indicated with light grey shading, while isolates with an MIC value 




Ceftaroline MIC (mg/L) 
Ceftobiprole MIC (mg/L) 








0.002 - - - - - - - - - - - - - 
0.004 - - - - - - - - - - - - - 
0.008 - - - - - - - - - - - - - 
0.015 - - - - - - - - - - - - - 
0.03 - - - - - - - - - - - - - 
0.06 - - - - - 4 3 1 - - - - 8 
0.125 - - - - 2 7 107 24 - - - - 140 
0.25 - - - - 3 1 218 1101 44 - - - 1367 
0.5 - - - - - - 2 64 118 8 - - 192 
1 - - - - - - - - 91 76 - - 167 
2 - - - - - - - - - 10 - - 10 
4 - - - - - - - - - - - - - 
8 - - - - - - - - - - - - - 






0.002 - - - - - - - - 1 - - - 1 
0.004 - - - - - - - - - - - - - 
0.008 - - 1 - - - - - - - - - 1 
0.015 - - - 1 2 0 2 1 - - - - 6 
0.03 - - 2 3 7 9 8 0 - - - - 29 
0.06 - - - 1 8 30 64 4 1 - - - 108 
0.125 - - - - 1 6 59 66 5 - - - 137 
0.25 - - - - - - 4 71 216 3 - - 294 
0.5 - - - - - - - 9 65 48 - - 122 
1 - - - - - - - - 3 45 11 - 59 
2 - - - - - - - - - 12 42 1 55 
4 - - - - - - - - - - 1 - 1 
8 - - - - - - - - - - - - - 











0.002 4 7 - - - - - - - - - - 11 
0.004 8 222 112 - - - - - - - - - 342 
0.008 - 111 740 14 - - - - - - - - 865 
0.015 - 3 89 44 9 1 - - - - - - 146 
0.03 - - 6 52 15 2 - - - - - - 75 
0.06 - - - 4 4 7 19 11 1 - - - 46 
0.125 - - - - - - 6 24 2 - - - 32 
0.25 - - - - - - - - 4 - - - 4 
0.5 - - - - - - - - 1 - - - 1 
1 - - - - - - - - - - - - - 
2 - - - - - - - - - - - - - 
4 - - - - - - - - - - - - - 
8 - - - - - - - - - - - - - 
Total 12 343 947 114 28 10 25 35 8 - - - 1522 
 
